Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small cell lung cancer with a PD-L1 expression level of >/= 1% by the U.S. Food and Drug Administration
Authors
Mountzios, GRemon, J
Novello, S
Blais, N
Califano, Raffaele
Cufer, T
Dingemans, A
Liu, SV
Peled, N
Pennell, NA
Reck, M
Rolfo, C
Tan, D
Vansteenkiste, J
West, H
Besse, B
Affiliation
Department of Medical Oncology, Henry Dunant Hospital Center, Athens, GreeceIssue Date
2019
Metadata
Show full item recordCitation
Mountzios G, Remon J, Novello S, Blais N, Califano R, Cufer T, et al. Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small cell lung cancer with a PD-L1 expression level of >/= 1% by the U.S. Food and Drug Administration. Ann Oncol. 2019 Sep 3.Journal
Annals of OncologyDOI
10.1093/annonc/mdz295PubMed ID
31504132Additional Links
https://dx.doi.org/10.1093/annonc/mdz295Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdz295
Scopus Count
Collections
Related articles
- FDA Approves 2 Therapies for Treatment of Metastatic Non-Small Cell Lung Cancer.
- Authors: Wright KM
- Issue date: 2020 Jun 10
- Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression.
- Authors: Aguilar EJ, Ricciuti B, Gainor JF, Kehl KL, Kravets S, Dahlberg S, Nishino M, Sholl LM, Adeni A, Subegdjo S, Khosrowjerdi S, Peterson RM, Digumarthy S, Liu C, Sauter J, Rizvi H, Arbour KC, Carter BW, Heymach JV, Altan M, Hellmann MD, Awad MM
- Issue date: 2019 Oct 1
- Q-TWiST Analysis to Assess Benefit-Risk of Pembrolizumab in Patients with PD-L1-Positive Advanced or Metastatic Non-small Cell Lung Cancer.
- Authors: Huang M, Pietanza MC, Samkari A, Pellissier J, Burke T, Chandwani S, Kong F, Pickard AS
- Issue date: 2019 Jan
- Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.
- Authors: Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Vandormael K, Riccio A, Yang J, Pietanza MC, Brahmer JR
- Issue date: 2019 Mar 1
- Baseline corticosteroids reduce activity of PD-L1 blockade.
- Authors: Gourd E
- Issue date: 2018 Oct